

Carole D Mitnick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4050170/publications.pdf>

Version: 2024-02-01

95
papers

4,755
citations

172457

29
h-index

98798

67
g-index

97
all docs

97
docs citations

97
times ranked

4098
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Among Market and City Bus Depot Workers in Lima, Peru. <i>Clinical Infectious Diseases</i> , 2022, 74, 343-346.	5.8	1
2	All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings. <i>European Respiratory Journal</i> , 2022, 59, 2004345.	6.7	5
3	FAST tuberculosis transmission control strategy speeds the start of tuberculosis treatment at a general hospital in Lima, Peru. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1459-1465.	1.8	3
4	Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort. <i>Clinical Infectious Diseases</i> , 2022, 75, 1006-1013.	5.8	26
5	Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs. <i>Clinical Infectious Diseases</i> , 2022, 75, 1307-1314.	5.8	14
6	Impact of out-of-pocket expenses for surgical care on households in rural Haiti: a mixed-methods study. <i>BMJ Open</i> , 2022, 12, e061731.	1.9	5
7	Diagnostic Performance Assessment of Saliva RT-PCR and Nasopharyngeal Antigen for the Detection of SARS-CoV-2 in Peru. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	2
8	Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 111-119.	5.6	36
9	TB research requires strong protections, innovation, and increased funding in response to COVID-19. <i>Trials</i> , 2021, 22, 371.	1.6	4
10	Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. <i>Trials</i> , 2021, 22, 651.	1.6	18
11	The Reductionist Conundrum of an "Updated" Definition of Extensively Drug-Resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 629-631.	5.6	0
12	INCIDENCE OF HIGH GRADE QTCF PROLONGATION AND ITS MANAGEMENT AMONG PATIENTS UNDERGOING TREATMENT FOR DRUG RESISTANT TUBERCULOSIS (DR-TB): CASE SERIES. <i>African Journal of Infectious Diseases</i> , 2021, 15, 38-41.	0.9	0
13	Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 71, 415-418.	5.8	16
14	Time-Dependent Confounding in Tuberculosis Treatment Outcome Analyses: A Review of a Source of Bias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1311-1314.	5.6	7
15	High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients. <i>Journal of Hepatology</i> , 2020, 72, 1028-1029.	3.7	7
16	Nepali Linguistic Validation of the Velopharyngeal Insufficiency Effects on Life Outcomes Instrument: VELO-Nepali. <i>Cleft Palate-Craniofacial Journal</i> , 2020, 57, 967-974.	0.9	3
17	A task-shifted speech therapy program for cleft palate patients in rural Nepal: Evaluating impact and associated healthcare barriers. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2020, 134, 110026.	1.0	6
18	Global Cash Flows for Sustainable Development: A Case Study of Accountability and Health Systems Strengthening in Lesotho. <i>Journal of Health Care for the Poor and Underserved</i> , 2020, 31, 56-74.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Comparison of censoring assumptions to reduce bias in tuberculosis treatment cohort analyses. PLoS ONE, 2020, 15, e0240297.	2.5	3
20	The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. BMC Infectious Diseases, 2019, 19, 733.	2.9	28
21	Value of observational data for multidrug-resistant tuberculosis. Lancet Infectious Diseases, The, 2019, 19, 930-931.	9.1	5
22	Disrupting a cycle of mistrust: A constructivist grounded theory study on patient-provider trust in TB care. Social Science and Medicine, 2019, 240, 112578.	3.8	16
23	Transmissibility and potential for disease progression of drug resistant <i>Mycobacterium tuberculosis</i> : prospective cohort study. BMJ: British Medical Journal, 2019, 367, l5894.	2.3	38
24	Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape. PLoS Medicine, 2019, 16, e1002767.	8.4	20
25	Tuberculosis active case-finding: more than just finding cases. Lancet Infectious Diseases, The, 2019, 19, 456-457.	9.1	0
26	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e93-e142.	5.6	282
27	Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1167-1168.	5.6	0
28	The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. European Respiratory Journal, 2019, 53, 1802089.	6.7	9
29	Time to revise WHO-recommended definitions of MDR-TB treatment outcomes. Lancet Respiratory Medicine, the, 2018, 6, 246-248.	10.7	11
30	Use of predicted vital status to improve survival analysis of multidrug-resistant tuberculosis cohorts. BMC Medical Research Methodology, 2018, 18, 166.	3.1	3
31	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	13.7	452
32	Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 657-666.	5.6	83
33	Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
34	Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis. International Journal of Tuberculosis and Lung Disease, 2018, 22, 473-474.	1.2	0
35	Has compassionate use ever sunk a drug?. International Journal of Tuberculosis and Lung Disease, 2018, 22, 119-120.	1.2	1
36	Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. International Journal of Infectious Diseases, 2017, 56, 185-189.	3.3	14

#	ARTICLE	IF	CITATIONS
37	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1490-1491.	5.6	1
38	Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance. <i>European Respiratory Journal</i> , 2017, 50, 1700598.	6.7	5
39	Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1364-1370.	5.8	17
40	A Bayesian response-adaptive trial in tuberculosis: The <i>endTB</i> trial. <i>Clinical Trials</i> , 2017, 14, 17-28.	1.6	32
41	An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 563.	1.6	17
42	Acquired and Transmitted Multidrug Resistant Tuberculosis: The Role of Social Determinants. <i>PLoS ONE</i> , 2016, 11, e0146642.	2.5	22
43	Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0151724.	2.5	12
44	Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. <i>PLoS ONE</i> , 2016, 11, e0155968.	2.5	22
45	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. <i>European Respiratory Journal</i> , 2016, 48, 1160-1170.	6.7	27
46	Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6766-6773.	3.2	12
47	Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. <i>BMC Infectious Diseases</i> , 2016, 16, 453.	2.9	29
48	Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1170-1171.	5.6	8
49	Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1028-1029.	5.6	16
50	Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru. <i>Global Pediatric Health</i> , 2016, 3, 2333794X1667438.	0.7	7
51	Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in <i>Mycobacterium tuberculosis</i> . <i>Journal of Clinical Microbiology</i> , 2016, 54, 727-733.	3.9	65
52	Using existing data to illustrate and close the gap in access to new anti-tuberculosis drugs. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 145-145.	1.2	1
53	Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 887-895.	5.8	64
54	Counting Pyrazinamide in Regimens for Multidrug-Resistant Tuberculosis. <i>Annals of the American Thoracic Society</i> , 2015, 12, 674-679.	3.2	21

#	ARTICLE	IF	CITATIONS
55	Risk factors for and origins of COPD. <i>Lancet, The</i> , 2015, 385, 1723-1724.	13.7	9
56	Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. <i>Lancet Respiratory Medicine</i> , 2015, 3, 201-209.	10.7	116
57	Access to new medications for the treatment of drug-resistant tuberculosis: Patient, provider and community perspectives. <i>International Journal of Infectious Diseases</i> , 2015, 32, 56-60.	3.3	36
58	Tuberculosis and chronic respiratory disease: a systematic review. <i>International Journal of Infectious Diseases</i> , 2015, 32, 138-146.	3.3	238
59	The need to accelerate access to new drugs for multidrug-resistant tuberculosis. <i>Bulletin of the World Health Organization</i> , 2015, 93, 491-497.	3.3	14
60	Time to Culture Conversion and Regimen Composition in Multidrug-Resistant Tuberculosis Treatment. <i>PLoS ONE</i> , 2014, 9, e108035.	2.5	28
61	Concordance of Resistance Profiles in Households of Patients With Multidrug-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2014, 58, 392-395.	5.8	14
62	Principles for designing future regimens for multidrug-resistant tuberculosis. <i>Bulletin of the World Health Organization</i> , 2014, 92, 68-74.	3.3	60
63	Improving Outcomes for Multidrug-Resistant Tuberculosis: Aggressive Regimens Prevent Treatment Failure and Death. <i>Clinical Infectious Diseases</i> , 2014, 59, 9-15.	5.8	45
64	Aggressive Regimens for Multidrug-Resistant Tuberculosis Reduce Recurrence. <i>Clinical Infectious Diseases</i> , 2013, 56, 770-776.	5.8	43
65	Reply to Seddon, Schaaf, and Hesselning. <i>Clinical Infectious Diseases</i> , 2013, 56, 168-169.	5.8	0
66	Planning for the invisible: projecting resources needed to identify and treat all patients with MDR-TB [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 427-428.	1.2	5
67	Tuberculosis in Children Exposed at Home to Multidrug-resistant Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 115-119.	2.0	23
68	Aggressive Regimens for Multidrug-Resistant Tuberculosis Decrease All-Cause Mortality. <i>PLoS ONE</i> , 2013, 8, e58664.	2.5	58
69	A Systematic Review of Reported Cost for Smear and Culture Tests during Multidrug-Resistant Tuberculosis Treatment. <i>PLoS ONE</i> , 2013, 8, e56074.	2.5	26
70	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. <i>PLoS Medicine</i> , 2012, 9, e1001300.	8.4	430
71	Eliminating the category "All retreatment regimen from national tuberculosis programme guidelines: the Georgian experience. <i>Bulletin of the World Health Organization</i> , 2012, 90, 63-66.	3.3	22
72	Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?. <i>European Respiratory Journal</i> , 2012, 40, 9-11.	6.7	30

#	ARTICLE	IF	CITATIONS
73	Old Drugs, New Purpose: Retooling Existing Drugs for Optimized Treatment of Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2012, 55, 572-581.	5.8	57
74	Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. <i>Tuberculosis</i> , 2012, 92, 397-403.	1.9	123
75	Rational use of moxifloxacin for tuberculosis treatment. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 259-260.	9.1	11
76	Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. <i>Lancet</i> , The, 2011, 377, 147-152.	13.7	119
77	Children and multidrug-resistant tuberculosis – Authors' reply. <i>Lancet</i> , The, 2011, 377, 1405.	13.7	2
78	Bayesian methods for fitting mixture models that characterize branching tree processes: An application to development of resistant TB strains. <i>Statistics in Medicine</i> , 2011, 30, 2708-2720.	1.6	1
79	Treatment Outcomes among Patients with Extensively Drug-Resistant Tuberculosis: Systematic Review and Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2010, 51, 6-14.	5.8	235
80	Encouraging News for Multidrug-resistant Tuberculosis Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1337-1338.	5.6	7
81	Recurrence after Treatment for Pulmonary Multidrug-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2010, 51, 709-711.	5.8	26
82	Preliminary clinical outcomes from the Peruvian National Cataract Elimination Plan. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2010, 28, 282-8.	1.1	1
83	Tuberculosis pharmacotherapy: strategies to optimize patient care. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 381-401.	1.8	85
84	Risk Factors and Mortality Associated with Default from Multidrug-Resistant Tuberculosis Treatment. <i>Clinical Infectious Diseases</i> , 2008, 46, 1844-1851.	5.8	121
85	Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2008, 359, 563-574.	27.0	364
86	Epidemiology and Treatment of Multidrug Resistant Tuberculosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 499-524.	2.1	37
87	Management of Extensively Drug-Resistant Tuberculosis in Peru: Cure Is Possible. <i>PLoS ONE</i> , 2008, 3, e2957.	2.5	55
88	Scaling Up Programmatic Management of Drug-Resistant Tuberculosis: A Prioritized Research Agenda. <i>PLoS Medicine</i> , 2008, 5, e150.	8.4	42
89	Randomized Trials to Optimize Treatment of Multidrug-Resistant Tuberculosis. <i>PLoS Medicine</i> , 2007, 4, e292.	8.4	63
90	Long-term Follow-up for Multidrug-resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2006, 12, 687-688.	4.3	19

#	ARTICLE	IF	CITATIONS
91	Multidrug-resistant Tuberculosis Management in Resource-limited Settings. <i>Emerging Infectious Diseases</i> , 2006, 12, 1389-1397.	4.3	152
92	Community-Based Therapy for Children With Multidrug-Resistant Tuberculosis. <i>Pediatrics</i> , 2006, 117, 2022-2029.	2.1	78
93	Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru. <i>New England Journal of Medicine</i> , 2003, 348, 119-128.	27.0	414
94	Informatics tools to monitor progress and outcomes of patients with drug resistant tuberculosis in Peru. <i>Proceedings</i> , 2002, , 270-4.	0.6	23
95	Health impact of human rights violations in Haitian refugees. <i>Lancet</i> , The, 1997, 350, 371-372.	13.7	3